Skip to Content

'
Garth Powis, D. Phil.

Present Title & Affiliation

Primary Appointment

David Bruton, Jr. Chair, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Professor and Chair, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Director, Center for Targeted Therapy, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Barnhart Family Distinguished Award in Targeted Therapies, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Garth Powis is leading the charge to coordinate all stages of the drug discovery and development process at The University of Texas M. D. Anderson Cancer Center. As director of the Center for Targeted Therapy and professor and chairman of the Department of Experimental Therapeutics, he believes that the academic environment is ideal for initiating and developing new therapies.

Since his recruitment to M. D. Anderson in 2005, Dr. Powis is steadily working to make the dream of personalized medicine a reality. The establishment of the Center for Targeted Therapy, a state-of-the-art facility slated for completion in 2010, will allow researchers and clinicians alike the ability to design new, specific and more effective drugs with less toxicity, targeted for individualized therapy. It is a mission that begins with a concept to identify molecular and genetic targets specific to each patient, continues with drug discovery and development and is followed by clinical trials. Bringing novel therapeutic and preventive drugs from the bench to the bedside, quicker than ever before, is his ultimate goal for the Center for Targeted Therapy.

A pioneer of the targeting of signaling pathways for cancer drug discovery, Dr. Powis is the author of four books. He has published more than 300 peer-reviewed articles and holds 11 patents in the area of cancer drug discovery and development. Dr. Powis is a member of the editorial board for several leading scientific publications including the Journals of Molecular Pharmacology, Molecular Cancer Therapeutics, Cancer Pharmacology and Therapeutics and Clinical Cancer Research. His research interests include mechanism of action of new anti-cancer drug, inhibition of P13K/AKT survival signaling and inhibition of redox and hypoxia signaling in cancer.  He has developed 3 cancer drugs, a thioredoxin inhibitor, a P13K inhibitor and a HIF-1alpha inhibitor that are currently in early clinical trial.

Research Interests

Exploiting Tumor Stress Response for Cancer Therapy

Solid tumors exist in a stressed environment for cell growth. In order to survive, cancer cells initiate specific adaptive and constitutive changes allowing them to adapt to the hostile hypoxic environment, escape cell death and increase formation of new blood vessels and metastasis. All of these responses lead to highly aggressive tumors that are resistant to therapy. In order to identify novel targets for therapeutic intervention that is applicable to a wide variety of tumor types, our lab studies the mechanisms that enable cancer cells to survive stress.

Please visit the Powis Lab.

Education & Training

Degree-Granting Education

1970 Merton College, Oxford, United Kingdom, D. Phil., Biochemistry and Pharmacology
1967 Birmingham University, England, United Kingdom, B.Sc., Hons. (1st Class), Biochemistry and Pharmacology

Selected Publications

Peer-Reviewed Original Research Articles

1. Powis G, Ihle N and Yung WKA. Inhibiting PI-3-K for glioma therapy. Cell Cycle 8(3):335-337, 2/2009. PMID: 19164951.
2. Ihle NT and Powis G. Take your PIK: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8(1):1-9, 1/2009. PMCID: PMC2775557.
3. Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 7(9):2621-32, 9/2008. PMCID: PMC2727864.
4. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come easy go. Trends Biochem Sci 33(11):526-534, 9/2008. PMID: 18809331.
5. Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 28(23):7081-95, 1/2008. PMCID: PMC2593390.
6. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular Mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia inducible factor-1 (alpha). Mol Cancer Ther 7(1):90-100, 2008. PMID: 18202012.

Last updated: 3/10/2010